Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau)

Prause, Lukas; Manka, Lukas; Millan, Christopher; Lang, Elena; Wyler, Stephen; Grobholz, Rainer; Hammerer-Lercher, Angelika; Sulser, Tullio; Recker, Franz; Kwiatkowski, Maciej; Eberli, Daniel

doi:10.1007/s00345-019-03054-5

Cited by 6 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current study showed that serum TXA 2 levels are increased in the PCa group with respect to healthy subjects. This finding is in agreement with that describing the involvement of prostanoids and chronic inflammation in carcinogenesis (36) and with the fact that aspirin intake reduced the PCa incidence (37). According to the literature (3,38), administration of ADT achieves reduced levels of FSH, LH, and testosterone in PCa patients to avoid tumor growth and spread.…”

Section: Discussionsupporting

confidence: 91%

Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A2: Cardiovascular Implications

Álvarez‐Maestro

Eguibar

Chanca

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Introduction: Androgens have been described as important players in the regulation of vascular function/structure through their action on the release and effect of vasoactive factors, such as prostanoids. Patients with prostate cancer (PCa) under androgen deprivation therapies (ADTs) present increased risk of cardiovascular mortality. Since thromboxane A2 (TXA2) is one of the most studied prostanoids and its involvement in different cardiovascular diseases has been described, the aim of this study was to investigate: (i) the effect of ADT on the serum levels of TXA2 in PCa patients and its possible link to the redox status and (ii) the effect of the non-hydrolyzable TXA2 analog U-46619 on the function of the aorta of male rats.Methods: The levels of TXA2 and total antioxidant status in 50 healthy subjects, 54 PCa patients, and 57 PCa under ADT were evaluated. These determinations were accompanied by levels of testosterone and C-reactive protein as an inflammation marker. In aortic segments from male rats, the U46619-induced effects on: (i) the vasomotor responses to acetylcholine (ACh), to the NO donor sodium nitroprusside (SNP), to the carbon monoxide-releasing molecule-3 (CORM-3), and to noradrenaline (NA) and (ii) the expression of cyclooxygenase-2 (COX-2), heme oxygenase-1 (HO-1), and phosphorylated ERK1/2 were analyzed.Results: The serum level of TXA2 in patients with PCa was increased with respect to healthy subjects, which was further increased by ADT. There was no modification in the total antioxidant status among the three experimental groups. In aortic segments from male rats, the TXA2 analog decreased the endothelium-dependent relaxation and the sensitivity of smooth muscle cells to NO, while it increased the vasoconstriction induced by NA; the expression of COX-2, HO-1, and pERK1/2 was also increased.Conclusions: ADT increased, along with other inflammatory/oxidative markers, the serum levels of TXA2. The fact that TXA2 negatively impacts the vascular function of the aorta of healthy male rats suggests that inhibition of TXA2-mediated events could be considered a potential strategy to protect the cardiovascular system.

show abstract

Section: Discussionsupporting

confidence: 91%

Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A2: Cardiovascular Implications

Álvarez‐Maestro

Eguibar

Chanca

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“… 24 The same conclusion was reached in recent research by Praise et al who analyzed the impact of Aspirin use on PSA levels and PCa development in a prospective screening study cohort of 4314 men from the Swiss section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). 16 They found that PSA values were significantly lower in ASA users at both baseline (1.6 vs 1.8 ng/mL, p = 0.007) and follow-up visits (1.75 vs 2.1 ng/mL, p < 0.001).…”

Section: Discussionmentioning

confidence: 95%

“…Considering all these aspects, several studies on anti-inflammatory drugs have been carried out to investigate the potential effect of reduction on lowering both PSA levels and the risk of PCa development. [11][12][13][14][15][16] A recent meta-analysis and population-based case-control studies examined the efficacy of NSAIDs and Acetylsalicylic acid (Aspirin) in preventing PCa: they found a significant 5-29% reduction in relative PCa risk compared with non-users. [17][18][19][20] On the other hand, the Nashville Men's Health Study suggests that PSA levels are significantly lower in Aspirin users with latent cancer.…”

Section: Introductionmentioning

confidence: 99%

Correlation Between Long-Term Acetylsalicylic Acid Use and Prostate Cancer Screening with PSA. Should We Reduce the PSA Cut-off for Patients in Chronic Therapy? A Multicenter Study

Mantica¹,

Chierigo²,

Cassim³

et al. 2022

RRU

View full text Add to dashboard Cite

Purpose To evaluate the prostate cancer (PCa) detection rate in men with chronic use of Aspirin and to compare it with the detection rate of non-users. Patients and Methods Prospectively maintained database regarding patients undergoing prostate biopsy over the last 10 years in five institutions. Patients were divided into two groups according to their exposure to Aspirin. We relied on multivariable linear and logistic regression models to test whether Aspirin administration was associated with lower PSA values at prostate biopsy, higher PCa diagnosis, and higher Gleason Grade Grouping (GGG) at biopsy. Results Were identified 1059 patients, of whom 803 (76%) did not take Aspirin vs 256 (24%) were taking it. In multivariable log-linear regression analysis, Aspirin administration was associated with lower PSA levels (OR 0.83, 95% CI 0.71–0.97, p = 0.01), after controlling for age, prostate volume, smoking history, associated inflammation at prostate biopsy, presence of PCa at biopsy, and GGG. In multivariable logistic regression analysis, Aspirin administration was not found to be a predictor of PCa at prostate biopsy (OR 1.40, 95% CI 0.82–2.40, p = 0.21) after controlling for age, PSA, smoking history, prostate volume, findings at digital rectal examination and the number of biopsy cores. In patients with PCa at prostate biopsy (n = 516), Aspirin administration was found to predict higher GGG (OR 2.24, 95% CI 1.01–4.87, p = 0.04). Conclusion Aspirin administration was found to be a predictor of more aggressive GGG. These findings suggest that a lower PSA threshold should be considered in patients taking Aspirin, as, despite low PSA levels, they might harbour aggressive PCa.

show abstract

“…Finally, a prospective study found that aspirin use is associated with lower PSA levels and cancer risk. 33 Study strengths & limitations. A key strength of this study is that it is a population-based study.…”

Section: Resultsmentioning

confidence: 99%

Association between body mass index and hemoglobin A1c with serum prostate-specific antigen level

Alhamdan,

Alsulaiman,

Alsabti

et al. 2023

SMJ

View full text Add to dashboard Cite

show abstract

Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau)

Cited by 6 publications

References 31 publications

Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A2: Cardiovascular Implications

Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A2: Cardiovascular Implications

Correlation Between Long-Term Acetylsalicylic Acid Use and Prostate Cancer Screening with PSA. Should We Reduce the PSA Cut-off for Patients in Chronic Therapy? A Multicenter Study

Association between body mass index and hemoglobin A1c with serum prostate-specific antigen level

Contact Info

Product

Resources

About